Summary
A combined i.v. and oral dosage regimen of metoprolol early in acute myocardial infarction has been evaluated. Metoprolol 15 mg i.v. in three divided doses followed by 200 mg orally in divided doses was administered to 20 patients. The median delay from onset of pain to start of treatment was 7.5 h. Following the i.v. dose absorption of the first oral dose was prolonged in several patients, but the plasma metoprolol concentration rapidly stabilized at a mean of about 200 nmol/l. A significant correlation was found between the change in resting heart rate and the plasma concentration of metoprolol 15 min after the start of treatment. Blood pressure was not correlated with metoprolol concentration. Nine patients were restudied after 16–19 days of chronic therapy. The time to maximal plasma concentration of metoprolol on chronic treatment was reduced compared to that observed after the first oral dose. The median minimum plasma concentration during steady state averaged around 200 nmol/l and was comparable to the mean trough levels 24 and 48 h after the start of therapy. In the majority of patients, the dosage regimen rapidly produced and maintained plasma levels of metoprolol which should induce a significant degree of beta-blockade.
Similar content being viewed by others
References
Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta-blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 27: 335–371
Hjalmarson Å, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Nyberg G, Rydén L, Swedberg K, Vedin A, Waagstein F, Waldenström A, Waldenström J, Wedel H, Wilhelmsen L, Wilhelmsson C (1981) Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 2: 823–827
The Miami Trial Research Group (1985) Metoprolol in acute myocardial infarction (MIAMI). A randomised placebocontrolled international trial. Eur Heart J 6: 199–226
Ekelund L-G, Johnsson G, Melcher A, Orö L (1976) Effects of cedilanid-D in combination with metoprolol on exercise tolerance and systolic time intervals in angina pectoris. Am J Cardiol 37: 630–634
Johnsson G, Regårdh C-G, Sölvell L (1975) Combined pharmacokinetic and pharmacodynamic studies in man of the adrenergic beta1-receptor antagonist metoprolol. Acta Pharmacol Toxicol 36 [Suppl V]: 31–44
Regårdh C-G, Johnsson G, Jordö L, Lundborg P, Persson B-A, Rönn O (1980) Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. J Cardiovasc Pharmacol 2: 715–723
Gugler R, Krist R, Raczinski H, Höffgen K, Bodem G (1980) Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs. Br J Clin Pharmacol 10: 337–343
Briant RH, Dorrington RE, Ferry DG, Paxton JW (1983) Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine. Eur J Clin Pharmacol 25: 353–356
Regårdh C-G, Johnsson G, Jordö L, Sölvell L (1975) Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. Acta Pharmacol Toxicol 36 [Suppl V]: 45–58
Jordö L, Attman P-O, Aurell M, Johansson L, Johnsson G, Regårdh C-G (1980) Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet 5: 169–180
Hässle Internal Report S-859 An effect study on metoprolol after multiple doses of controlled release formulation, conventional tablets and placebo. Responsible investigator P Lundborg (in press)
Kjekshus J (1985) Comments — Beta-blockers: Heart rate reduction a mechanism of benefit. Eur Heart J 6 [Suppl A]: 29–30
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Held, P.H., Regårdh, C.G. Metoprolol in acute myocardial infarction. A pharmacokinetic and pharmacodynamic study. Eur J Clin Pharmacol 31, 261–265 (1986). https://doi.org/10.1007/BF00981121
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00981121